Finally, new migraine drugs

Successful phase 3 data for new headache medications (rimegepant, ubrogepant, lasmiditan) are finally raining in after a lengthy drought. Also today, interferon status and family history predict autoimmune connective tissue disease, steroid injection before rotator cuff repair predicts revision, and the CMS resumes risk adjustment payments for 2017. Listen to the MDedge Daily News for today’s top news.